Maslov Dmitry L, Trifonova Oxana P, Lichtenberg Steven, Balashova Elena E, Mamedli Zaman Z, Alferov Aleksandr A, Stilidi Ivan S, Lokhov Petr G, Kushlinskii Nikolay E, Archakov Alexander I
Institute of Biomedical Chemistry, 10 Building 8, Pogodinskaya Street, 119121 Moscow, Russia.
Metabometrics Inc., 651 N Broad Street, Suite 205 #1370, Middletown, DE 19709, USA.
Cancers (Basel). 2022 Dec 26;15(1):140. doi: 10.3390/cancers15010140.
Early diagnostics significantly improves the survival of patients with renal cell carcinoma (RCC), which is the prevailing type of adult kidney cancer. However, the absence of clinically obvious symptoms and effective screening strategies at the early stages result to disease progression and survival rate reducing. The study was focused on revealing of potential low molecular biomarkers for early-stage RCC. The untargeted direct injection mass spectrometry-based metabolite profiling of blood plasma samples from 51 non-cancer volunteers (control) and 78 patients with different RCC subtypes and stages (early stages of clear cell RCC (ccRCC), papillary RCC (pRCC), chromophobe RCC (chrRCC) and advanced stages of ccRCC) was performed. Comparative analysis of the blood plasma metabolites between the control and cancer groups provided the detection of metabolites associated with different tumor stages. The designed model based on the revealed metabolites demonstrated high diagnostic power and accuracy. Overall, using the metabolomics approach the study revealed the metabolites demonstrating a high value for design of plasma-based test to improve early ccRCC diagnosis.
早期诊断显著提高了肾细胞癌（RCC）患者的生存率，肾细胞癌是成人肾癌的主要类型。然而，早期缺乏明显的临床症状和有效的筛查策略导致疾病进展和生存率降低。该研究的重点是揭示早期肾细胞癌潜在的低分子生物标志物。对51名非癌症志愿者（对照组）以及78名患有不同肾细胞癌亚型和分期（透明细胞肾细胞癌（ccRCC）早期、乳头状肾细胞癌（pRCC）、嫌色细胞肾细胞癌（chrRCC）和ccRCC晚期）患者的血浆样本进行了基于非靶向直接进样质谱的代谢物谱分析。对对照组和癌症组之间的血浆代谢物进行比较分析，检测出了与不同肿瘤分期相关的代谢物。基于所揭示代谢物设计的模型显示出较高的诊断能力和准确性。总体而言，该研究通过代谢组学方法揭示了一些代谢物，这些代谢物对于设计基于血浆的检测方法以改善早期ccRCC诊断具有很高价值。
